Advanced Solid Tumors
Clinical research activity includes metastatic and locally advanced unresectable solid tumors that have progressed after standard therapies, with attention to treatment-resistant disease settings and tumour response in heavily pretreated populations.
- Metastatic or locally advanced unresectable solid tumors
- Tumors progressing after available standard therapies
- Objective response in difficult-to-treat cancers
The sponsor’s oncology portfolio in this area reflects a strong interest in late-line cancer treatment across heterogeneous solid malignancies.
Non-Small Cell Lung Cancer
Research includes advanced and metastatic non-small cell lung cancer, with evaluation of both standalone and combination treatment approaches in a disease setting with substantial unmet need.
- Advanced non-small cell lung cancer
- Metastatic non-small cell lung cancer
- Combination therapy in lung cancer
These studies place emphasis on tumour control and tolerability in patients with progressive lung malignancies.
Gynecologic Cancers
The sponsor is active in cervical cancer, endometrial cancer, and ovarian cancer, covering multiple major gynecologic malignancies with distinct clinical profiles and treatment challenges.
- Cervical cancer
- Endometrial cancer
- Ovarian cancer
This focus spans recurrent and advanced disease contexts where new therapeutic options are sought.
Genitourinary Malignancies
Clinical trial activity also extends to prostate cancer and urothelial carcinoma, reflecting interest in both hormone-driven and urothelial tumour biology.
- Prostate cancer
- Urothelial carcinoma
- Advanced genitourinary cancer
These areas support investigation in advanced disease where durable disease control remains an important therapeutic goal.
Combination Oncology Therapy
Several studies examine combination therapy in solid tumors, including regimens paired with pembrolizumab, indicating a research interest in integrating novel anticancer agents with established immune-based treatment strategies.
- Solid tumors
- Combination with pembrolizumab
- Safety and efficacy in combination regimens
The therapeutic emphasis is on expanding treatment options for advanced cancers through multi-agent oncology approaches.
